{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:03:40Z","timestamp":1784347420895,"version":"3.55.0"},"reference-count":27,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7672-26","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:10:43Z","timestamp":1784326243000},"source":"Crossref","is-referenced-by-count":0,"title":["Isavuconazole Therapy for Nasal-Cerebral Mucormycosis with High Isavuconazole MIC"],"prefix":"10.2169","author":[{"given":"Takeo","family":"Mori","sequence":"first","affiliation":[{"name":"Department of General Medicine and Emergency Care (Infectious Diseases), Toho University Omori Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Kamiyama","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Toho University Omori Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakura","family":"Koyama","sequence":"additional","affiliation":[{"name":"Postgraduate Clinical Training Center, Toho University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Nakase","sequence":"additional","affiliation":[{"name":"Department of General Medicine and Emergency Care (Infectious Diseases), Toho University Omori Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of General Medicine and Emergency Care (Infectious Diseases), Toho University Omori Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of General Medicine and Emergency Care (Infectious Diseases), Toho University Omori Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taito","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of General Medicine and Emergency Care (Infectious Diseases), Toho University Omori Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of General Medicine and Emergency Care (Infectious Diseases), Toho University Omori Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misaki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Toho University Omori Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Toho University Omori Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Division of Clinical Research, Medical Mycology Research Center, Chiba University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadako","family":"Yoshizawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Toho University Omori Medical Center, Japan"},{"name":"Department of Microbiology and Infectious Diseases, Toho University School of Medicine, Japan"},{"name":"Department of Laboratory Medicine, Toho University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Tateda","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Infectious Diseases, Toho University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of General Medicine and Emergency Care, Toho University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 19: e405-e421, 2019."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Chikley A, Ben-Ami R, Kontoyiannis DP. Mucormycosis of the central nervous system. J Fungi (Basel) 5: 59, 2019.","DOI":"10.3390\/jof5030059"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 387: 760-769, 2016.","DOI":"10.1016\/S0140-6736(15)01159-9"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Wilby KJ. A review of the clinical pharmacokinetics and pharmacodynamics of isavuconazole. Eur J Drug Metab Pharmacokinet 43: 281-290, 2018.","DOI":"10.1007\/s13318-017-0445-7"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Wiederhold NP, Kovanda L, Najvar LK, et al. Isavuconazole is effective for the treatment of experimental cryptococcal meningitis. Antimicrob Agents Chemother 60: 5600-5603, 2016.","DOI":"10.1128\/AAC.00229-16"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 54 (Suppl 1): S23-S34, 2012.","DOI":"10.1093\/cid\/cir866"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 47: 503-509, 2008.","DOI":"10.1086\/590004"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Yohai RA, Bullock JD, Aziz AA, Markert RJ. Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol 39: 3-22, 1994.","DOI":"10.1016\/S0039-6257(05)80041-4"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Lanternier F, Poiree S, Elie C, et al. Prospective pilot study of high-dose (10 mg\/kg\/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. J Antimicrob Chemother 70: 3116-3123, 2015.","DOI":"10.1093\/jac\/dkv236"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 182: 274-282, 2000.","DOI":"10.1086\/315643"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Strenger V, Meinitzer A, Donnerer J, et al. Amphotericin B transfer to CSF following intravenous administration of liposomal amphotericin B. J Antimicrob Chemother 69: 2522-2526, 2014.","DOI":"10.1093\/jac\/dku148"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Collette N, van der Auwera P, Lopez AP, Heymans C, Meunier F. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother 33: 362-368, 1989.","DOI":"10.1128\/AAC.33.3.362"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Collette N, Van der Auwera P, Meunier F, Lambert C, Sculier JP, Coune A. Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients. J Antimicrob Chemother 27: 535-548, 1991.","DOI":"10.1093\/jac\/27.4.535"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Felton T, Troke PF, Hope WW. Tissue penetration of antifungal agents. Clin Microbiol Rev 27: 68-88, 2014.","DOI":"10.1128\/CMR.00046-13"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection 45: 737-779, 2017.","DOI":"10.1007\/s15010-017-1042-z"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Desai A, Kovanda L, Kowalski D, Lu Q, Townsend R, Bonate PL. Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi. Antimicrob Agents Chemother 60: 5483-5491, 2016.","DOI":"10.1128\/AAC.02819-15"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Schmitt-Hoffmann A, Roos B, Maares J, et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 50: 286-293, 2006.","DOI":"10.1128\/AAC.50.1.286-293.2006"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Lamoth F, Mercier T, Andr\u00e9 P, et al. Isavuconazole brain penetration in cerebral aspergillosis. J Antimicrob Chemother 74: 1751-1753, 2019.","DOI":"10.1093\/jac\/dkz050"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Schwartz S, Cornely OA, Hamed K, et al. Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system. Med Mycol 58: 417-424, 2020.","DOI":"10.1093\/mmy\/myz103"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Garcia-Vidal C, Gallardo-Pizarro A, Aiello TF, Martinez-Urrea A, Teijon-Lumbreras C, Monzo-Gallo P. Experience with isavuconazole in the treatment of mucormycosis and breakthrough fungal infections. Rev Iberoam Micol 42: 51-54, 2025.","DOI":"10.1016\/j.riam.2025.01.005"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Gunathilaka SS, Keragala RK, Gunathilaka KM, et al. Use of isavuconazole in mucormycosis: a systematic review. BMC Infect Dis 25: 25, 2025.","DOI":"10.1186\/s12879-025-10439-y"},{"key":"22","unstructured":"22. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi. 3rd ed. CLSI standard M38. Clinical and Laboratory Standards Institute, Wayne, PA, 2017."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Jenks JD, Salzer HJ, Prattes J, Krause R, Buchheidt D, Hoenigl M. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy. Drug Des Devel Ther 12: 1033-1044, 2018.","DOI":"10.2147\/DDDT.S145545"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Ellsworth M, Ostrosky-Zeichner L. Isavuconazole: Mechanism of action, clinical efficacy, and resistance. J Fungi (Basel) 6: 324, 2020.","DOI":"10.3390\/jof6040324"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Lewis JS 2nd, Wiederhold NP, Hakki M, Thompson GR 3rd. New perspectives on antimicrobial agents: Isavuconazole. Antimicrob Agents Chemother 66: e0017722, 2022.","DOI":"10.1128\/aac.00177-22"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Hosoda R, Suzuki S, Hosoda S, et al. Successful allogeneic hematopoietic stem cell transplantation for AML with pulmonary mucormycosis under isavuconazole. J Infect Chemother 31: 102790, 2025.","DOI":"10.1016\/j.jiac.2025.102790"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Yasu T, Hoshino M, Sakamoto N, Kobayashi M. Successful isavuconazole treatment for pulmonary mucormycosis in a patient intolerant to liposomal amphotericin B with pharmacokinetic insights: A case report. Chemotherapy 69: 244-249, 2024.","DOI":"10.1159\/000539652"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7672-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:25:49Z","timestamp":1784345149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7672-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":27,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7672-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7672-26"}}